New device may reduce radiation exposure to patients with liver cancer
the ONA take:
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer undergoing intra-arterial therapy (IAT), according to a report to be presented at the Radiological Society of North America annual meeting in Chicago.
In a clinical trial, Jean-Francois Geschwind, MD, and fellow researchers at Johns Hopkins University School of Medicine and Kimmel Cancer Center used the device on 50 patients, the researchers found that it was able to reduce exposure by up to 80 percent compared to standard X-ray platforms for IAT. In addition, AlluraClarity produced images that were just as clear as the standard system.
Dr. Geschwind believes that the novel platform will be especially useful in patients who require repeat therapy and are especially vulnerable to radiation such as children, as well as physicians who are regularly exposed to radiation procedures.
AlluraClarity uses a series of real-time image processing algorithms in order to achieve high quality images that require lower radiation power. It is developed by Philips Healthcare.
AlluraClarity has the potential to reduce radiation exposure in patients with liver cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|